Hypothesized role of pregnancy hormones on HER2+ breast tumor development

Giovanna I. Cruz, María Elena Martínez, Loki Natarajan, Betsy C. Wertheim, Manuela Gago-Dominguez, Melissa Bondy, Adrian Daneri-Navarro, María Mercedes Meza-Montenegro, Luis Enrique Gutierrez-Millan, Abenaa Brewster, Pepper Schedin, Ian K. Komenaka, J. Esteban Castelao, Angel Carracedo, Carmen M. Redondo, Patricia A. Thompson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalBreast Cancer Research and Treatment
Volume137
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Hormones
Breast Neoplasms
Pregnancy
Progesterone Receptors
Estrogen Receptors
Neoplasms
Odds Ratio
Confidence Intervals
Logistic Models
Triple Negative Breast Neoplasms
Incidence
Mexico
Hispanic Americans
Spain
Breast
Population

Keywords

  • Breast cancer
  • Breast tumor subtypes
  • Etiologic heterogeneity
  • HER2
  • Hispanic
  • Parity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cruz, G. I., Martínez, M. E., Natarajan, L., Wertheim, B. C., Gago-Dominguez, M., Bondy, M., ... Thompson, P. A. (2013). Hypothesized role of pregnancy hormones on HER2+ breast tumor development. Breast Cancer Research and Treatment, 137(1), 237-246. https://doi.org/10.1007/s10549-012-2313-0

Hypothesized role of pregnancy hormones on HER2+ breast tumor development. / Cruz, Giovanna I.; Martínez, María Elena; Natarajan, Loki; Wertheim, Betsy C.; Gago-Dominguez, Manuela; Bondy, Melissa; Daneri-Navarro, Adrian; Meza-Montenegro, María Mercedes; Gutierrez-Millan, Luis Enrique; Brewster, Abenaa; Schedin, Pepper; Komenaka, Ian K.; Castelao, J. Esteban; Carracedo, Angel; Redondo, Carmen M.; Thompson, Patricia A.

In: Breast Cancer Research and Treatment, Vol. 137, No. 1, 01.2013, p. 237-246.

Research output: Contribution to journalArticle

Cruz, GI, Martínez, ME, Natarajan, L, Wertheim, BC, Gago-Dominguez, M, Bondy, M, Daneri-Navarro, A, Meza-Montenegro, MM, Gutierrez-Millan, LE, Brewster, A, Schedin, P, Komenaka, IK, Castelao, JE, Carracedo, A, Redondo, CM & Thompson, PA 2013, 'Hypothesized role of pregnancy hormones on HER2+ breast tumor development', Breast Cancer Research and Treatment, vol. 137, no. 1, pp. 237-246. https://doi.org/10.1007/s10549-012-2313-0
Cruz GI, Martínez ME, Natarajan L, Wertheim BC, Gago-Dominguez M, Bondy M et al. Hypothesized role of pregnancy hormones on HER2+ breast tumor development. Breast Cancer Research and Treatment. 2013 Jan;137(1):237-246. https://doi.org/10.1007/s10549-012-2313-0
Cruz, Giovanna I. ; Martínez, María Elena ; Natarajan, Loki ; Wertheim, Betsy C. ; Gago-Dominguez, Manuela ; Bondy, Melissa ; Daneri-Navarro, Adrian ; Meza-Montenegro, María Mercedes ; Gutierrez-Millan, Luis Enrique ; Brewster, Abenaa ; Schedin, Pepper ; Komenaka, Ian K. ; Castelao, J. Esteban ; Carracedo, Angel ; Redondo, Carmen M. ; Thompson, Patricia A. / Hypothesized role of pregnancy hormones on HER2+ breast tumor development. In: Breast Cancer Research and Treatment. 2013 ; Vol. 137, No. 1. pp. 237-246.
@article{babcfd1eefe6455a9a8568a4dad056cb,
title = "Hypothesized role of pregnancy hormones on HER2+ breast tumor development",
abstract = "Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 {\%} confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 {\%} CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 {\%} CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.",
keywords = "Breast cancer, Breast tumor subtypes, Etiologic heterogeneity, HER2, Hispanic, Parity",
author = "Cruz, {Giovanna I.} and Mart{\'i}nez, {Mar{\'i}a Elena} and Loki Natarajan and Wertheim, {Betsy C.} and Manuela Gago-Dominguez and Melissa Bondy and Adrian Daneri-Navarro and Meza-Montenegro, {Mar{\'i}a Mercedes} and Gutierrez-Millan, {Luis Enrique} and Abenaa Brewster and Pepper Schedin and Komenaka, {Ian K.} and Castelao, {J. Esteban} and Angel Carracedo and Redondo, {Carmen M.} and Thompson, {Patricia A.}",
year = "2013",
month = "1",
doi = "10.1007/s10549-012-2313-0",
language = "English (US)",
volume = "137",
pages = "237--246",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Hypothesized role of pregnancy hormones on HER2+ breast tumor development

AU - Cruz, Giovanna I.

AU - Martínez, María Elena

AU - Natarajan, Loki

AU - Wertheim, Betsy C.

AU - Gago-Dominguez, Manuela

AU - Bondy, Melissa

AU - Daneri-Navarro, Adrian

AU - Meza-Montenegro, María Mercedes

AU - Gutierrez-Millan, Luis Enrique

AU - Brewster, Abenaa

AU - Schedin, Pepper

AU - Komenaka, Ian K.

AU - Castelao, J. Esteban

AU - Carracedo, Angel

AU - Redondo, Carmen M.

AU - Thompson, Patricia A.

PY - 2013/1

Y1 - 2013/1

N2 - Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.

AB - Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.

KW - Breast cancer

KW - Breast tumor subtypes

KW - Etiologic heterogeneity

KW - HER2

KW - Hispanic

KW - Parity

UR - http://www.scopus.com/inward/record.url?scp=84871735036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871735036&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2313-0

DO - 10.1007/s10549-012-2313-0

M3 - Article

C2 - 23135573

AN - SCOPUS:84871735036

VL - 137

SP - 237

EP - 246

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -